|
Title
|
|
|
|
Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer : a pooled meta-analysis
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Several retrospective and prospective studies have shown that genomic alterations in Estrogen-receptor one (ESR1) can be characterized not only in tissue samples but also by sequencing circulating tumor DNA (ctDNA) in liquid biopsy. Therefore, liquid biopsy is a potential noninvasive surrogate for tissue biopsy. This meta-analysis was designed to compare the prevalence of ESR 1 mutation detected with liquid biopsy and tissue biopsy. A pooled meta-analysis of studies published between 1 January 2007 and 1 March 2021 was conducted regarding the methodologies used for ESR1 mutation analysis. Liquid biopsy is a valid, inexpensive, and attractive noninvasive alternative to tumor biopsies for the identification of ESR1 mutations. Liquid biopsy for ESR 1 analysis would facilitate regular testing, allowing monitoring of the sensitivity to ET and guiding treatment strategies. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Frontiers in oncology / Frontiers Research Foundation (Lausanne, Switzerland) - [Lausanne, 2011, currens
|
|
|
Publication
|
|
|
|
Lausanne
:
Frontiers media sa
,
2023
|
|
|
ISSN
|
|
|
|
2234-943X
|
|
|
DOI
|
|
|
|
10.3389/FONC.2023.1221773
|
|
|
Volume/pages
|
|
|
|
13
(2023)
, p. 1-12
|
|
|
Article Reference
|
|
|
|
1221773
|
|
|
ISI
|
|
|
|
001058494700001
|
|
|
Pubmed ID
|
|
|
|
37675216
|
|
|
Medium
|
|
|
|
E-only publicatie
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (open access)
|
|
|
|
|
|